21st week of 2009 patent applcation highlights part 41 |
Patent application number | Title | Published |
20090130058 | BIOLOGICALLY ACTIVE COMPOSITION COMPRISING ETHYLCELLULOSE - A biologically active composition comprising an ethylcellulose, a polyethylene oxide and a biologically active ingredient, wherein the amount of ethylcellulose is at least about (15) percent, based on the total weight of the composition, can be used in melt-extrusion processes to produce pharmaceutical dosage forms. | 2009-05-21 |
20090130059 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2009-05-21 |
20090130060 | Modified Vitamin K Dependent Polypeptides - The present invention relates to modified cDNA sequences coding for vitamin K-dependent polypeptides, in particular human Factor VII, human Factor VIIa, human Factor IX and human protein C and their derivatives with improved stability and extended plasma half life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences. | 2009-05-21 |
20090130061 | Adenovirus vectors containing cell status-specific response elements and methods of use thereof - The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors. | 2009-05-21 |
20090130062 | Novel Application of Heparin-Binding Epidermal Growth Factor-Like Growth Factor for Medical Purposes - The present invention provides an agent for protecting the liver and/or promoting liver regeneration, which contains a heparin-binding EGF-like growth factor-like growth factor (HB-EGF) or a partial peptide thereof, or a nucleic acid that encodes same, and an agent for the prophylaxis or treatment of liver diseases. The present invention further provides a method for producing a cell for liver protection and/or promoting liver regeneration, and for the prophylaxis/treatment of a liver disease, which includes introducing a nucleic acid that encodes HB-EGF or a partial peptide thereof into a cell collected from an animal. | 2009-05-21 |
20090130063 | PROCESS FOR SEPARATING AND DETERMINING THE VIRAL LOAD IN A PANCREATIN SAMPLE - Processes for separating a viral load from a pancreatin sample and for quantitatively determining the viral load in a pancreatin sample with high sensitivity are described herein. | 2009-05-21 |
20090130064 | DIFFERENTIATION OF STEM CELLS AND STABILIZATION OF PHENOTYPICAL PROPERTIES OF PRIMARY CELLS - Methods of inducing differentiation of stem cells and stem cells obtained are disclosed. A method for stabilizing the phenotype of isolated primary cells in vitro is disclosed. In both methods, a central role is played by histone deacetylase inhibitors. | 2009-05-21 |
20090130065 | Multipotent adult stem cells - Isolated human multipotent adult stem cell and isolated populations of cells that include human multipotent adult stem cells are disclosed. Human hair-follicle derived multipotent adult stem cells and methods of preparing isolated populations of cells that include human multipotent adult stem cells are disclosed. Isolated human hair-follicle derived multipotent adult stem cell that can differentiate in culture into a neuronal cell, a glial cell, a melanocyte cell, a muscle cell, an osteocyte, a chondrocyte, and a lymphocyte. Isolated human hair-follicle derived multipotent adult stem cell that can grow in cell culture in spheres are disclosed. Human pancreas derived multipotent adult stem cells, human liver derived multipotent adult stem cells, human kidney derived multipotent adult stem cells, human heart derived multipotent adult stem cells, human neural derived multipotent adult stem cells and methods of preparing isolated populations of cells that include such human multipotent adult stem cells are disclosed. Method of treating an individual who has diabetes, cardiac muscle damage, muscle damage and disease, neurodegenerative disease or nerve damage or injury, bone loss, damage and/or disease, cartilage loss, damage and/or disease, hair loss and immune disorders, are disclosed. | 2009-05-21 |
20090130066 | AUGMENTATION AND REPAIR OF SPHINCTER DEFECTS WITH CELLS INCLUDING MUSCLE CELLS - An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or direct surgical placement/implantation of autologous cultured cells and/or cultured cell-produced extracellular matrix that is derived from connective tissue, dermis, fascia, lamina propria, stroma, adipose tissue, muscle, tendon, ligament or the hair follicle. The corrective application is done on tissue proximal or within the area of the defect. The method involves retrieving viable cells from the subject, a neonate or human fetus. Alternatively, the corrective application involves the cells placed in a matrix, preferably comprised of autologous extracellular matrix constituents as a three-dimensional structure or as a suspension, prior to placement into a position with respect to the subject's defect. In a further embodiment, the preferable autologous extracellular matrix constituents are collected from culture and placed in a position with respect to the subjects defect. | 2009-05-21 |
20090130067 | Cell Population Having Immunoregulatory Activity, Method for Isolation and Uses - The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues. | 2009-05-21 |
20090130068 | Oral Tissue Regeneration and Repair - A method for treating an oral condition of a subject by grafting cultured tissue constructs to the oral tissue. The cultured tissue constructs comprise cultured cells and endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. Some tissue constructs of the invention are comprised of multiple cell layers or more than one cell type. The tissue constructs of the invention have morphological features and functions similar to tissues their cells are derived and their strength makes them easily handleable. Preferred cultured tissue constructs of the invention comprise cells derived from human tissue. | 2009-05-21 |
20090130069 | Thymidine Kinase - A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered. | 2009-05-21 |
20090130070 | METHOD OF TREATMENT - The present invention discloses the use of fetuin and fetuin producing agents in methods and compositions for treating burn injuries in animals. | 2009-05-21 |
20090130071 | Soybean Plant And Seed Corresponding To Transgenic Event MON87701 And Methods For Detection Thereof - The present invention provides a transgenic soybean event MON87701, and cells, seeds, and plants comprising DNA diagnostic for the soybean event. The invention also provides compositions comprising nucleotide sequences that are diagnostic for said soybean event in a biological sample, probes and primers for use in detecting nucleotide sequences that are diagnostic for the presence of said soybean event in a biological sample, and methods for detecting the presence of said soybean event nucleotide sequences in a biological sample. The invention further provides methods of growing the seeds of such soybean event into soybean plants, and methods of breeding to produce soybean plants comprising DNA diagnostic for the soybean event. | 2009-05-21 |
20090130072 | Use of Lactobacillus Kefiranofaciens as a Probiotic and a Synbiotic - In accordance with the present invention, there is provided a probiotic composition comprising an effective amount of | 2009-05-21 |
20090130073 | Microorganisms Inhibiting the Formation of Foot Malodor - Described are microorganisms which are able to inhibit the formation of foot malodor by skin microorganisms. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications. | 2009-05-21 |
20090130074 | PREPARATION OF ANTIGEN-PRESENTING HUMAN GAMMA DELTA T CELLS AND USE IN IMMUNOTHERAPY - Cytotoxic αβ T cells form an essential component in immunity to infections and tumors, and are also implicated in host defense against these challenges. The present disclosure demonstrates the ability of activated γδ T cells to cross-present exogenous antigens to CD8 | 2009-05-21 |
20090130075 | ENERGY GENERATING COMPOSITION - The present invention is drawn to an ephedra- and artificial stimulant-free energy promoting composition, comprising effective amounts of a magnesium amino acid chelate, a B vitamin, a pyruvate salt, and rhodiola. These ingredients work synergistically together to provide energy, without the use of artificial stimulants, caffeine, or ephedrine. Additional amino acid chelates can also be present, such as iron amino acid chelate, zinc amino acid chelate, copper amino acid chelate, manganese amino acid chelate, chromium amino acid chelate, and mixtures of second amino acid chelates. | 2009-05-21 |
20090130076 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS - The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I: | 2009-05-21 |
20090130077 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS - The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I: | 2009-05-21 |
20090130078 | Treatment for Cardiovascular Disease - This invention relates to a method for treating and preventing hypertension by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment. Additionally, the scope of the invention includes a method of treating coronary heart disease by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment. | 2009-05-21 |
20090130079 | INTRAVENTRICULAR ENZYME DELIVERY FOR LYSOSOMAL STORAGE DISEASES - Lysosomal storage diseases can be successfully treated using intraventricular delivery of the enzyme which is etiologically deficient in the disease. The administration can be performed slowly to achieve maximum effect. Surprisingly, effects are seen on both sides of the blood-brain barrier, making this an ideal delivery means for lysosomal storage diseases which affect both brain and visceral organs. | 2009-05-21 |
20090130080 | PLACENTAL ALKALINE PHOSPHATASE TO CONTROL DIABETES - The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier. | 2009-05-21 |
20090130081 | Method for treating pervasive development disorders - A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with a PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level. | 2009-05-21 |
20090130082 | Compositions and methods for the treatment and prevention of infections caused by staphylococcus aureus bacteria - The present invention relates to antimicrobial deoxyribonuclease-based compositions that inhibit growth and proliferation of | 2009-05-21 |
20090130083 | Therapeutic Agents Targeting the NCCA-ATP Channel and Methods of Use Thereof - The present invention is directed to therapeutic compositions targeting the NC | 2009-05-21 |
20090130084 | Tagged IgA1 proteases - The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed. | 2009-05-21 |
20090130085 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations - The invention relates to novel compounds of the formula (I) and their use in stabilization of Factor Vila or other Factor VII polypeptides, particularly in aqueous liquid compositions thereof. | 2009-05-21 |
20090130086 | FXIII Variants with Improved Properties - The present invention concerns variant factor XIII, wherein the rate of activation of said variant by thrombin is faster than for wild type FXIII. Methods for enhancing fibrin clot formation, pharmaceutical compositions and the use for the manufacture of medicaments wherein the variant factor XIII is applied are disclosed. | 2009-05-21 |
20090130087 | METHOD FOR MEASURING THE CONTENT OF A BOTULINUM TOXIN IN A FORMULATION - A method of measuring the concentration of a bioactive agent is disclosed. | 2009-05-21 |
20090130088 | Compositions and methods for regulating RNA translation via CD154 CA-dinucleotide repeat - Compositions and methods for regulating CD154 gene expression are provided that rely on the interaction of hnRNP L with the CA-dinucleotide rich sequence of the 3′-untranslated region of CD154. | 2009-05-21 |
20090130089 | ANTI-CD20 ANTIBODIES AND METHODS OF USE - Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is achieved by having at least one optimized CDR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD20 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD20 antibodies. | 2009-05-21 |
20090130090 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists - New antagonists of the interaction between the CCR1 Chemokine receptor and its ligands, including MIP-1α (CCL3), represented by formula (I) are disclosed, as well as pharmaceutical compositions comprising them and their use in therapy for the treatment of pathological conditions or diseases susceptible of being improved by antagonism of the CCR1 receptor. | 2009-05-21 |
20090130091 | COMPOUNDS FOR HEDGEHOG PATHWAY BLOCKADE IN PROLIFERATIVE DISORDERS, INCLUDING HEMATOPOIETIC MALIGNANCIES - Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in hematopoietic malignancy cells, and determined to be associated with growth and proliferation of the malignancy cells. Accordingly, methods are provided for treating a hematopoietic cell malignancy associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of determining the responsiveness of a hematopoietic cell malignancy to treatment with an Hh pathway antagonist. | 2009-05-21 |
20090130092 | NUCLEOTIDE PHOSPHATE DISSIPATION AS A TREATMENT FOR VASCULAR DISORDERS - The present invention provides a method of treating or preventing immunoinflammatory, vascular, thrombotic or ischemic disorders in a subject, the method comprises administering to the subject an agent which dissipates nucleotide phosphates or generates a product which stimulates adenosine receptors. The present invention also provides a method of treating or preventing immunoinflammatory, thrombotic or ischemic disorders in a subject by inhibiting leukocyte infiltration into a site which comprises administering to the subject an effective amount a described agent. Agents described for use in the methods of the invention include CD73, a fragment a mutant, or a modified form thereof. | 2009-05-21 |
20090130093 | BINDING MEMBER FOR GM-CSF RECEPTOR - Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFRα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis. | 2009-05-21 |
20090130094 | Cytotoxic Antibodies Directed Against Antibodies Inhibiting Factor VIII - The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the FcγRIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A. | 2009-05-21 |
20090130095 | ANTI-CD40 ANTIBODIES CAPABLE OF BLOCKING B-CELL ACTIVATION - Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented. | 2009-05-21 |
20090130096 | Gene Signature of Early Hypoxia to Predict Patient Survival - The present invention provides methods and compositions for predicting patient responses to cancer treatment using hypoxia gene signatures. These methods can comprise measuring in a biological sample from a patient the levels of gene expression of a group of the genes designated herein. The present invention also provides for microarrays that can detect expression from a group of genes. | 2009-05-21 |
20090130097 | Quinazolinone Compounds and Methods of Use Thereof - The present invention relates to quinazolinone compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the quinazolinone compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a quinazolinone compound of the present invention | 2009-05-21 |
20090130098 | Specific therapy using integrin ligands for treating cancer - The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone, concurrently or not in the dosage regime of the present invention. | 2009-05-21 |
20090130099 | HUMANIZED ANTIBODIES AND COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P. | 2009-05-21 |
20090130100 | METHODS OF USING HUMANIZED ANTIBODIES AND COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P. | 2009-05-21 |
20090130101 | ANTI-CANCER THERAPY WITH AN EXTRACT OF SCUTELLARIA BARBATA - Methods of treating cancer with a combination of an extract of | 2009-05-21 |
20090130102 | METHODS FOR HUMANIZING ANTIBODIES AND HUMANIZED ANTIBODIES MADE THEREBY - Disclosed herein is the use of three-dimensional structure information to guide the process of modifying antibodies with amino acids from one or more templates or surrogates such that the antigen binding properties of the parent antibody are maintained and the immunogenicity potential is reduced when administered as a therapeutic in humans. | 2009-05-21 |
20090130103 | PURIFICATION AND PROTECTIVE EFFICACY OF MONODISPERSE AND MODIFIED YERSINIA PESTIS CAPSULAR F1-V ANTIGEN FUSION PROTEINS FOR VACCINATION AGAINST PLAGUE - This disclosure concerns compositions and methods for the treatment and inhibition of infectious disease, particularly bubonic and pneumonic plague. In certain embodiments, the disclosure concerns immunogenic proteins, for instance substantially monodisperse F1-V fusion proteins, that are useful for inducing protective immunity against | 2009-05-21 |
20090130104 | FUSION PROTEINS FOR INHIBITION AND DISSOLUTION OF COAGULATION - Fusion proteins containing a ligand which specifically binds to a selected vascular bed linked to an anti-thrombotic molecule are provided. Also provided are methods for use of these fusion proteins to prevent coagulation, to dissolve blood clots and to protect against the risk of iatrogenic side effects including those arising from cancer therapy and specific vascular occluding agents. | 2009-05-21 |
20090130105 | COMPOSITIONS THAT BIND MULTIPLE EPITOPES OF IGF-1R - The instant invention is based, at least in part on the finding that binding molecules which bind to different epitopes within IGF-1R result in improved IGF-1 and/or IGF-2 blocking capabilities when compared to binding molecules that bind to a single IGF-1R epitope. The instant invention provides compositions that bind to multiple epitopes of IGF-1R, for example, combinations of monospecific binding molecules or multispecific binding molecules (e.g., bispecific molecules). Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize IGF-1R signaling are also provided. | 2009-05-21 |
20090130106 | DEMIBODIES: DIMERIZATION-ACTIVATED THERAPEUTIC AGENTS - The present invention relates generally to a set of synthetic immunointeractive molecules referred to herein as “demibodies” which are useful in targeting particular cells in a subject. More particularly, the present invention provides a set of demibodies wherein at least two molecules from within the set, each specific for a different antigen on a target cell, are required to interact together at the cell surface in order to form an active complex which directs demibody-mediated cellular or complement mediated cytotoxicity and/or reporter function and/or therapeutic activity. The demibodies of the present invention are useful in the targeting of particular cells such as cancer cells including leukemic cells, pathogens including malarial, bacterial and viral agents, and stem cells including embryonic and adult stem cells and pathogen cells. The present invention provides, therefore, methods of treatment, diagnosis and undertaking research and compositions comprising demibodies useful for same. | 2009-05-21 |
20090130107 | INTERLEUKIN-22 POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE SAME AND METHODS FOR THE TREATMENT OF PANCREATIC DISORDERS - The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 2009-05-21 |
20090130108 | N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy - The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that overexpress N-cadherin and Ly6-E, including prostrate and bladder cancers. The invention further provides methods of drug discovery to identify pharmaceutical agents that inhibit or prevent the binding of N-cadherin and Ly6-E to its receptor, which are useful when used alone or in combination with known chemotherapeutics, immunotherapeutics, and radiotherapy for the reversal of resistance, tumor progression, and metastasis of cancers associated with the overexpession of N-cadherin and Ly6-E. | 2009-05-21 |
20090130109 | DCL-1 and uses thereof - The present invention relates generally to a novel lectin and to derivatives, homologues, analogues, chemical equivalents and mimetics thereof and, more particularly, to a novel type I C-type lectin, herein referred to as “DCL-1”. In particular, the present invention relates to the use of DCL-1 in therapeutic, prophylactic and diagnostic applications. | 2009-05-21 |
20090130110 | HIGH AFFINITY FULLY HUMAN MONOCLONAL ANTIBODIES TO INTERLEUKIN-8 AND EPITOPES FOR SUCH ANTIBODIES - The present embodiments are related to high-affinity antibodies directed to IL-8, methods of making and characterizing such antibodies and uses of such antibodies. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. | 2009-05-21 |
20090130111 | Method of Identifying Membrane Ig Specific Antibodies and Use Thereof for Targeting Immunoglobulin-Producing Precursor Cells - The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. | 2009-05-21 |
20090130112 | SPATIAL FOR ALTERING CELL PROLIFERATION - This disclosure provides methods useful for altering cell proliferation by modifying SPATIAL activity in cells. In some methods, thymocyte numbers in subjects with disease-associated immunodeficiencies are increased by administering an agent that inhibits SPATIAL activity. Also provided are methods useful for increasing thymocyte number in a subject by administering an agent that interferes with an interaction between SPATIAL and Uba3. In other methods, cell growth is inhibited by introducing or expressing a SPATIAL or SPATIAL-related polypeptide or nucleic acid in one or more cell(s), such as neoplastic cell(s). Further provided are methods of identifying agents that modify (for example, inhibit) SPATIAL expression or activity, or which interfere with an interaction between SPATIAL and Uba3 polypeptides, and therefore which are useful in influencing thymocyte number. | 2009-05-21 |
20090130113 | Compositions and methods for use for antibodies against sclerostin - The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat disease related to bone abnormalities such as osteoporosis. An embodiment of the invention herein provides an antibody or a functional protein comprising an antigen-binding portion of said antibody for a target in sclerostin polypeptide, characterized in that the antibody or functional protein specifically binds to sclerostin polypeptide and can increase at least one of bone formation, bone mineral density, bone mineral content, bone mass, bone quality and bone strength in a mammal. | 2009-05-21 |
20090130114 | WISE BINDING AGENTS AND EPITOPES - The present invention relates to binding agents for WISE, and includes for their manufacture and use. | 2009-05-21 |
20090130115 | ANTIBODIES RECOGNIZING A HIGHLY EXPRESSED PUTATIVE ANTIGEN OF CA-MRSA AND METHODS OF USE - The present invention provides MSCRAMM® proteins from | 2009-05-21 |
20090130116 | Use of CEACAM8-Specific Substances for Treating Autoimmune Diseases and a Method for Screening Substances Which Induce Apoptosis - The invention relates to the use of substances which are specific to CEACAM8 for the manufacture of a medicament for the prophylactic or therapeutic treatment of human autoimmune diseases and/or gout. Another object of the invention concerns the use of CEACAM8-specific substances for apoptosis induction in-vitro. The invention also relates to a method for screening substances which induce apoptosis and a method for inducing apoptosis in human granulocytes. | 2009-05-21 |
20090130117 | Substituted Tetrazole Compounds and Uses Thereof - The present invention provides tetrazole compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the tetrazole compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention. | 2009-05-21 |
20090130118 | SCUTELLARIA BARBATA EXTRACT AND COMBINATIONS FOR THE TREATMENT OF CANCER - An extract of | 2009-05-21 |
20090130119 | ANTI-CTLA-4 ANTIBODY COMPOSITIONS - The present invention provides for novel compositions of anti-CTLA-4 antibodies comprising a chelating agent. Also provided are method of treating diseases and conditions with novel compositions of CTLA-4 antibodies, including various neoplasia conditions. | 2009-05-21 |
20090130120 | ANTI-RSV G PROTEIN ANTIBODIES - Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections. | 2009-05-21 |
20090130121 | Synthetic Peptide Copolymers for Treatment and Prevention of Cardiovascular Disorders - The present invention relates to the use of random or ordered copolymers including the known copolymer glatiramer (also known as Copolymer 1) and Copolymer 1-related heteropolymers or ordered peptides, for treating or preventing cardiovascular diseases and disorders. | 2009-05-21 |
20090130122 | Methods for treating rheumatoid arthritis using IL-17 antagonists - A method of treating a mammal afflicted with rheumatoid arthritis comprising administering a soluble form of IL-17 receptor is disclosed. | 2009-05-21 |
20090130123 | Antibodies to west nile virus polypeptides - The present invention relates to anti-West Nile virus E protein (WNE) antibodies, including human antibodies, and antigen-binding portions thereof. In particular, the invention relates to such antibodies and portions that prevent, inhibit, or treat a flavivirus infection, including a West Nile Virus infection. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or that are portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-WNE antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-WNE antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis, prophylaxis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-WNE antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention. | 2009-05-21 |
20090130124 | Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration - The present invention satisfies the need in the art by providing methods for altering hematopoietic progenitor cell adhesion and/or migration to a target tissue, and for altering hematopoietic progenitor cell differentiation into a second cell type. The invention also provides methods for screening test compounds for altering the level of hematopoietic progenitor cell adhesion and/or migration to a target tissue, and for altering hematopoietic progenitor cell differentiation into a second cell type. The invention further provides methods for isolating hematopoietic progenitor cells. | 2009-05-21 |
20090130125 | COMBINATION OF TUMOR-ASSOCIATED SURFACE PROTEIN ANTIGENS AND TUMOR-ASSOCIATED SUGARS IN THE TREATMENT AND DIAGNOSIS OF CANCER - The invention relates to a kit for the combined use for the treatment of cancer patients, which set comprises an antigen of a cellular surface protein, or an antibody directed against the cellular surface protein, and an antigen of an aberrant glycosylation, or an antibody directed against the aberrant glycosylation. This kit is destined both for the immunotherapeutic and the diagnostic application. The invention further relates to a selection method for selecting suitable tumor-specific antigens with the assistance of this kit and corresponding specific antibody preparations. | 2009-05-21 |
20090130126 | DNA EXPRESSION VECTORS - The invention relates to DNA vectors containing a transcription regulatory sequence derived from Human Cytomegalovirus major immediate early gene that includes exon 1, but not intron A. Vectors, host cells, pharmaceutical and vaccine compositions comprising such host cells and vectors are contemplated. | 2009-05-21 |
20090130127 | Adjuvant or Pharmaceutical Preparation for Transdermal or Transmucousal Administration - An adjuvant for transdermal or transmucosal administration which comprises at least one substance selected from an aliphatic alcohol, a free fatty acid and a fatty acid derivative but does not contain a substance represented by the following formula: wherein R | 2009-05-21 |
20090130128 | Antiinfective Proanthocyanidin Compounds and Methods of Use Thereof - One aspect of the invention relates to novel proanthocyandin compounds that are useful as antiinfective agents. In one embodiment, the invention relates to a pure and isolated compound of formula I or II: | 2009-05-21 |
20090130129 | Melanoma-associated endogenous retrovirus (MERV) derived peptide sequences and their therapeutic/diagnostic use - The present invention provides antigenic polypeptides derived from the melanoma-associated endogenous retrovirus (MERV). These antigens are useful compounds for the detection of cancerous cells and melanoma-diagnosis as well as melanoma-prognosis. Furthermore these antigenic polypeptides of the present invention form the basis for anti-cancer vaccines. | 2009-05-21 |
20090130130 | MUTANT ALLERGEN(S) - There is provided an isolated polypeptide, derivative, isoform and/or fragment thereof, wherein the polypeptide is a mutant of a Group 5 allergen. There are also provided pharmaceutical compositions(s) and vaccine(s) for the treatment of subjects allergic to at least one Group 5 allergen. | 2009-05-21 |
20090130131 | Antigen-Drug Vehicle Enabling Switch From Selective Production of IgA Antibody to Production of Both of IgA and IgG Antibodies and Transnasal/Mucosal Vaccine Using the Same - In the aim of practical utilization of a safe and effective transnasal/inactivated/mucosal vaccine and establishment of a technology for imparting capacity of producing both of IgA and IgG antibodies to a conventional inactivated vaccine, toxoid; allergen, or the like, a means for prevention and treatment of allergy, and the like, it is intended to provide an antigen-drug vehicle (AD vehicle) enabling transnasal, transmucosal, and transdermal administrations, an inactivated vaccine simultaneously inducing a mucosal immunity and humoral immunity by using the AD vehicle, a production method of the inactivated vaccine, an AD vehicle enabling a switch from induction of selective production of IgA antibody to induction of both of IgA and IgG antibodies, and a transnasal vaccine, a mucosal vaccine, a therapeutic/prophylactic agent for allergy, and the like using the AD vehicle. | 2009-05-21 |
20090130132 | Anti-caveolin-1 polyclonal antibody, and antigen peptide sequence and method for preparing the same - The present invention provides a highly specific anti-Caveolin-1 polyclonal antibody, which is prepared by the following steps: (1) providing an antigen comprising a fragment of Caveolin-1 peptide sequence SEQ ID NO: 1; and (2) subcutaneously injecting said antigen into a rabbit to produce the anti-Caveolin-1 polyclonal antibody. The present invention also provides an antigen and a method used for preparing the anti-Caveolin-1 polyclonal antibody, and a kit used for detecting Caveolin-1 in a specimen. | 2009-05-21 |
20090130133 | IMMUNOGENIC POLYPEPTIDE COMPOSED OF TUMOR ANTIGEN-DERIVED OPTIMIZED CRYPTIC PEPTIDES, AND USES THEREOF - The present invention pertains to the field of anti-cancer vaccines. More particularly, the invention concerns an optimized polypeptide, which comprises three cryptic tumor peptides with enhanced immunogenicity and comprises the amino acids sequence YLQVNSLQTVYLEYRQVPVYLEEITGYL, for use in an anti-cancer vaccine. Nucleic acids encoding such a polypeptide, as well as complexes and dendritic cells engineered with this polypeptide or a nucleic acid encoding it, are also part of the invention. | 2009-05-21 |
20090130134 | T CD4+ Epitopes of Type I and II Latency Antigens of the Epstein-Barr Virus, Which Can Be Recognized by the majority of individuals in the caucasian populations and applications thereof - The invention relates to immunogenic peptides from EBV type I and II latency antigens, comprising at least one T CD4+ epitope which can be recognized by the majority of individuals in the Caucasian population. The invention also relates to the diagnostic and therapeutic applications of same. | 2009-05-21 |
20090130135 | HCV VACCINES - Disclosed are methods and compositions for inducing immune responses against Hepatitis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided. | 2009-05-21 |
20090130136 | Chondroitin Sulphate a Binding Domains - The invention is related to the identification of CSA binding domains in var2CSA homologs from different parasite strains and furthermore to an isolated polypeptide comprising a CSA-binding domain sequence substantially as shown in SEQ ID NO:1, or functional equivalent thereof, or the corresponding portion of PfEMP1 from a strain of | 2009-05-21 |
20090130137 | MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of | 2009-05-21 |
20090130138 | Antiviral and antibacterial activity from medicinal mushrooms - Compounds having unique antiviral and antibacterial properties are prepared from medicinal mushroom mycelium, extracts and derivatives. The compositions are derived from | 2009-05-21 |
20090130139 | Cosmetic active ingredient composed of arginine ferrulate and a microalgae extract and its uses - The invention relates to a novel cosmetic active ingredient composed of a microalgae extract and arginine ferrulate, its uses for activating proteasome and the production of thioredoxin, a cosmetic composition containing it and the use of such a cosmetic composition for combating skin ageing. | 2009-05-21 |
20090130140 | Capsular Polysaccharide Solubilisation and Combination Vaccines - Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1. | 2009-05-21 |
20090130141 | Compositions and methods for stimulating an immune response against infectious agents - The invention provides for oral compositions for safely stimulating an immune response to mucoadhesive antigens for protection against infectious agents, particularly influenza viruses using heat-labile, mutant | 2009-05-21 |
20090130142 | Streptococcus Phocae Vaccine - The present invention relates to the use of bacteria of the species | 2009-05-21 |
20090130143 | N PROTEIN MUTANTS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS - The present invention provides a genetically modified PRRS virus, methods to make it and related polypeptides, polynucleotides and various components. Vaccines comprising the genetically modified virus and polynucleotides are also provided. | 2009-05-21 |
20090130144 | Direct vaccination of the bone marrow - The present invention provides methods for eliciting an effective immune response against a weakly immunogenic disease or for priming T cells to become memory T cells against a weakly immunogenic disease by directly vaccinating into the bone marrow of the patient an antigen associated with the weakly immunogenic disease. Also included in the present invention is an isolated population of human memory CD8 | 2009-05-21 |
20090130145 | VACCINE - The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue. | 2009-05-21 |
20090130146 | COMBINATION VACCINE - The present invention relates to the combination of antigens directed against bacteria and viruses, their uses and the preparation of medicaments in order to confer protection against infectious diseases. In particular, the invention relates to a combination vaccine comprising at least one antigen of | 2009-05-21 |
20090130147 | Capsular polysaccharide solubilisation and combination vaccines - Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1. | 2009-05-21 |
20090130148 | MYCOPLASMA BOVIS VACCINE AND METHODS OF USE THEREOF - The present invention relates to new attenuated | 2009-05-21 |
20090130149 | BIOACTIVE COPEPOD-COMPOSITIONS, PROCESSES FOR THE PRODUCTION THEREOF, AND USE THEREOF TO PREVENT OR TREAT HOSTS INFESTED BY PHYLOGENETICALLY SIMILAR ECTOPARASITES - The present invention relates to novel compositions comprising copepods, such as marine | 2009-05-21 |
20090130150 | Biologically Active Nanoparticles A Carbonate-Substituted Hydroxyapatite, Process For Their Preparation And Compositions Incorporating The Same - The invention relates to biologically active nanoparticles of a carbonate-substituted non-stoichiometric hydroxyapatite, having:
| 2009-05-21 |
20090130151 | DISPERSION OF NATURAL OILS AND/OR SYNTHETIC ESSENTIAL OILS IN WATER - The invention relates to process for the production of an emulsion, comprising combining an aqueous liquid with a non-aqueous liquid mixture to form a combination, removing dissolved gases from both the aqueous liquid and the non-aqueous liquid mixture and agitating the combination sufficient to form the emulsion. The non-aqueous liquid mixture is immiscible with the aqueous liquid, and combination is formed in the absence of an emulsion stabilizing agent. | 2009-05-21 |
20090130152 | COSMETIC COMPOSITION COMPRISING AN OIL - The present invention relates to a composition for making up or caring for the skin having a volatile fraction, a non-volatile fraction and comprising at least one dispersed solid phase and a liquid fatty phase comprising: —at least one oil chosen from dry oils chosen from oils with a viscosity of less than or equal to 10 Cps, a surface tension of between 21 and 31 mN/m and an evaporation rate of less than 0.002 mg/cm2/minute, the said dispersed solid phase being present in the composition in a content such that the volume fraction of the dispersed solid phase is greater than or equal to 55% by volume and in particular ranges from 55% to 98% by volume relative to the total volume of the non-volatile fraction of the composition. The invention also relates to the use of the said composition for obtaining a uniform makeup that does not transfer, that shows good staying power and/or is comfortable. | 2009-05-21 |
20090130153 | Emulsifier Combination, Emulsion Containing the Emulsifier Combination, and a Process for its Production - An emulsifier concentrate containing: (a) a C | 2009-05-21 |
20090130154 | Topical Delivery of Biological and Cosmetic Agents by Zeolites - The present invention discloses certain di- and polyvalent metal zeolite compounds (formula I) for topical delivery of biological and skin and hair care agents. The method of treating skin and hair condition via topical application of said zeolite compounds is also disclosed. The said method provides a treatment for topical condition, which includes alleviation of skin conditions such as skin rash including diaper rash, dry skin, scalp dandruff, broken or chafed skin, sunburn, skin damage from UV, skin irritation, acne including excess facial oil and facial pore size; darkened skin including age spots, dark circles around the eyes, and discoloration of skin from stretch marks; skin aging including wrinkles and fine lines; loss of collagen including thinning skin and loss of skin pliability; body odor, including oral cavity odor, arm-pit odor, and incontinence odor; cellular inflammation including intracellular and extra cellular inflammation; premature hair aging including premature hair loss hair graying; malfunction of tyrosinase group of enzymes, malfunction of matrix metalloprotease group of enzymes; and combinations thereof. The said method also provides topical delivery of certain metals, including trace metals, and certain zirconium aluminum amino acids that provide antiperspirant benefits; | 2009-05-21 |
20090130155 | Biologically Active Formulation - The present invention provides a formulation characterised by the simultaneous presence in cyclodextrin based supramolecular complexes, of two components, one of which possesses insecticidal, acaricidal, fungicidal, snailcidal or vermicidal activity and the other possesses an activity synergistic with the first, enhancing its effectiveness. The biologically active substance is chosen from the following classes of chemical products: carbamates, organophosphates, thioureas, pentatomic or hexatomic heterocycles in which 1, 2 or 3 nitrogen atoms are present. The synergistic substance can be chosen from components containing at least one aromatic or non aromatic carbocyclic ring, such as piperonyl butoxide, sesamol, verbutin or MGK 264. For the same dose, the activity of the present formulations is greater than that of the mixture of the two active components alone or separately complexed with cyclodextrin. The process for preparing said formulation and its use for the activities herein indicated are further aspects of the present invention. | 2009-05-21 |
20090130156 | INNOVATIVE FORMULATION - The present invention relates to a new formulation characterised by the presence of two components, one of which (A) possesses insecticidal, acaricidal, fungicidal, snailcidal or vermicidal activity and the other (B) exhibits synergistic activity with the first by enhancing its effectiveness, and in which the average release time of component (A) is 1 to 12 hours later than the average release time of component (B). The formulation is obtained by: a) separate microencapsulation of both components (A) and (B) within a multilayer system of specific polymers in which component (A) is in a more interior portion of the capsule than component (B), being separated from component (B) by a polymer layer of suitable thickness (FIG. | 2009-05-21 |
20090130157 | Antimicrobial Adhesive Films - A multi-layer film for reducing microbial contamination on a surface. The multi-layer film can include a core layer having a first surface and a second surface opposite the first surface, an adhesive layer disposed adjacent the first surface of the core layer, and an antimicrobial layer disposed adjacent the second surface. The antimicrobial layer can include a cross-linked matrix and an antimicrobial agent dispersed within the cross-linked matrix, where the cross-linked matrix is derived from a polymerizable precursor comprising a material selected from the group consisting of a polymerizable monomer, a polymerizable polymer having a molecular weight of about 1,000 or less, and combinations thereof. | 2009-05-21 |